About General Prognostics
General Prognostics is a company based in Boston (United States) founded in 2020 by Javier Echenique, Sean Matsuoka, and Sidhant Jena. General Prognostics has raised $3.25 million across 5 funding rounds from investors including UMass Lowell, NEC X and D4V. General Prognostics operates in a competitive market with competitors including iRhythm Tech, AliveCor, Biotricity, Cardiotrack and Element Science, among others.
- Headquarter Boston, United States
- Founders Javier Echenique, Sean Matsuoka, Sidhant Jena
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$3.25 M (USD)
in 5 rounds
-
Latest Funding Round
Not available
-
Investors
UMass Lowell
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of General Prognostics
General Prognostics has successfully raised a total of $3.25M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in General Prognostics
General Prognostics has secured backing from 5 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include UMass Lowell, NEC X and D4V.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
NEC X is engaged in supporting early-stage tech startups.
|
Locked | Locked | Locked | |
|
Venture capital firm focusing on Japanese startups
|
Locked | Locked | Locked | |
|
Undergraduate and graduate education programs are provided across disciplines.
|
Locked | Locked | Locked |
Investor details for General Prognostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by General Prognostics
Investment portfolio details for General Prognostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - General Prognostics
Detailed financials for General Prognostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
General Prognostics Comparisons
Peer comparison for General Prognostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of General Prognostics
General Prognostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as iRhythm Tech, AliveCor, Biotricity, Cardiotrack and Element Science, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cloud-based ambulatory ECG monitors for cardiac arrhythmia diagnosis are provided.
|
|
| Locked | Locked | Locked |
Cardiac monitoring devices and applications are provided for heart health.
|
|
| Locked | Locked | Locked |
Developer of medical remote monitoring solutions that help prevent and manage chronic diseases
|
|
| Locked | Locked | Locked |
AI-based EGC data capture and analysis platform
|
|
| Locked | Locked | Locked |
Wearable patch defibrillators are developed for sudden cardiac arrest treatment.
|
|
| Locked | Locked | Locked |
Online health and wellness tracking and training platform
|
Detailed competitors of General Prognostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on General Prognostics
Complete news archive for General Prognostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about General Prognostics
General Prognostics was founded in 2020.
General Prognostics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Javier Echenique is the current CEO of General Prognostics. They have also founded this company.
General Prognostics is a funded company, having raised a total of $3.25M across 5 funding rounds to date.
General Prognostics was founded in 2020 in Boston, United States, and operates in the healthcare sector. AI-driven tools for health monitoring are developed, focusing on biomarker-based remote solutions for cardio-renal diseases. Blood analysis and remote monitoring capabilities are included, along with presymptomatic detection of critical conditions in patients. Services target healthcare professionals for improved patient outcomes.
General Prognostics's top competitors include AliveCor, iRhythm Tech and Biotricity.
General Prognostics has 5 investors. Key investors include UMass Lowell, NEC X, D4V, Pete Moran, and Hiroaki Kitano.